Artiva Biotherapeutics (NASDAQ:ARTV) Insider Subhashis Banerjee Sells 7,037 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 7,037 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $63,403.37. Following the transaction, the insider directly owned 144,963 shares in the company, valued at approximately $1,306,116.63. This represents a 4.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV traded down $0.67 during mid-day trading on Tuesday, reaching $8.55. 844,679 shares of the company’s stock were exchanged, compared to its average volume of 581,930. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53. The firm has a market capitalization of $211.36 million, a PE ratio of -2.42 and a beta of 2.86. The business’s fifty day simple moving average is $8.32 and its two-hundred day simple moving average is $5.65.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its holdings in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at approximately $131,000. OMERS ADMINISTRATION Corp acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth approximately $91,000. Finally, Sanctuary Advisors LLC acquired a new stake in Artiva Biotherapeutics during the 1st quarter worth approximately $139,000.

Analyst Ratings Changes

Several equities analysts have commented on ARTV shares. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Cantor Fitzgerald raised their target price on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Finally, Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.